

Special Issue

Exploring Metabolomics and Other Biomarkers for Osteosarcopenic Adiposity Detection, Prevention and Management

Message from the Guest Editor

The purpose of this Special Issue is to bring more insight into the metabolic nature of OSA by investigating the following:

1. Biomarkers for each tissue (bone, muscle, adipose) which, in combination, may indicate the existing impairments and presence of OSA, possibly discovering/identifying or proposing the series of omics.
2. In view of recent technological advances, such as genomic sequencing and molecular targeted drug exploitation, the concept of precision medicine can be used to demarcate OSA using multiple data sources from genomics to digital health metrics to artificial intelligence in order to facilitate an individualized yet “evidence-based” decisions regarding diagnostic and therapeutic approaches. In this way, therapeutics can be centered toward patients based on their molecular presentation rather than grouping them into broad categories with a “one size fits all” approach.
3. Any type of review or research article is welcome.

Guest Editor

Prof. Dr. Jasminka Ilich-Ernst

Institute for Successful Longevity, Florida State University, Tallahassee, FL 32306, USA

Deadline for manuscript submissions

closed (31 May 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/189080

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/jpm)

[jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).